文献速递类风湿关节炎

类风湿关节炎患者骨折风险相关药物分析

Medications associated with fracture risk in patients with rheumatoid arthritis.
PubMed 文献 · Ann Rheum Dis · 2019-05-15

调整混杂因素后,糖皮质激素、阿片类药物及选择性5-羟色胺再摄取抑制剂(SSRIs)与任何骨折风险增加相关,而他汀和肿瘤坏死因子抑制剂(TNFi)仅与椎体骨折风险降低相关。

要点

  • 糖皮质激素≥3个月、阿片类药物及SSRIs与任何骨折风险增加相关。
  • 他汀和TNFi仅与椎体骨折风险降低相关。
  • PPIs和其他精神类药物未显示骨折风险增加。

核心结论

  • 使用阿片类药物、SSRIs和糖皮质激素与类风湿关节炎患者任何骨折风险增加相关。
  • 他汀和TNFi与椎体骨折风险降低相关。

研究设计与样本

  • 基于FORWARD纵向观察注册队列,纳入2001至2017年美国类风湿关节炎无既往骨折患者。
  • 采用按FRAX分层的Cox比例风险模型调整混杂因素。

主要发现

  • 任何剂量糖皮质激素≥3个月与骨折风险增加相关:<7.5 mg/天 HR 1.26(95%CI 1.07-1.48),≥7.5 mg/天 HR 1.57(95%CI 1.27-1.94)。
  • 阿片类药物与骨折风险增加相关:弱阿片类 HR 1.37(95%CI 1.18-1.59),强阿片类 HR 1.53(95%CI 1.24-1.88)。
  • SSRIs与骨折风险增加相关:HR 1.37(95%CI 1.15-1.63);使用>3个月 HR 1.25(95%CI 1.01-1.55)。
  • 阿片类药物使用1个月内骨折风险增加:HR 1.66(95%CI 1.36-2.04)。
  • 他汀(HR 0.77,95%CI 0.62-0.96)和TNFi(HR 0.72,95%CI 0.54-0.97)仅与椎体骨折风险降低相关。

关键数值与推荐

  • 骨折部位包括骨质疏松相关部位:椎体、髋部、前臂和肱骨。
  • DMARD暴露分为四组:甲氨蝶呤单药治疗(参照)、TNFi、非TNFi生物制剂和其他。
  • 非DMARD药物和糖皮质激素按当前/曾经使用及治疗持续时间分类。
  • 计算FRAX评分估计10年主要骨质疏松性骨折风险。

临床怎么用

  • 对类风湿关节炎患者使用糖皮质激素、阿片类药物或SSRIs时应评估骨折风险并加强监测。
  • 他汀和TNFi可能对椎体骨折具有保护作用,但需结合个体情况解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the fracture risk with use of disease-modifying antirheumatic drugs (DMARDs), statins, proton pump inhibitors (PPIs), opioids, non-opioid analgesics and psychotropic medications in a US-wide observational rheumatoid arthritis (RA) cohort. METHODS: Patients with RA without prior fracture from 2001 through 2017 in FORWARD, a longitudinal observational registry, were assessed for osteoporosis-related site fractures (vertebra, hip, forearm and humerus). DMARD exposure was assessed in four mutually exclusive groups: (1) methotrexate monotherapy-reference, (2) tumour necrosis factor-α inhibitors (TNFi), (3) non-TNFi biologics and (4) others. Non-DMARDs and glucocorticoids were classified as current/ever use and based on treatment duration. Fracture Risk Assessment Tool (FRAX) scores estimating for 10-year major osteoporotic fractures were calculated. Cox proportional hazard models stratified by FRAX were used to adjust for confounders. RESULTS: During median (IQR) 3.0 (1.5-6.0) years of follow-up in 11 412 patients, 914 fractures were observed. The adjusted models showed a significant fracture risk increase with use of any dose glucocorticoids ≥3 months (HR (95% CI) for <7.5 mg/day 1.26 (1.07 to 1.48) and for ≥7.5 mg/day 1.57 (1.27 to 1.94)), opioids (for weak: 1.37 (1.18 to 1.59); strong: 1.53 (1.24 to 1.88)) and selective serotonin reuptake inhibitors (SSRIs) (1.37 (1.15 to 1.63)). Fracture risk with opioids increased within 1 month of use (1.66 (1.36 to 2.04)) and with SSRIs >3 months of use (1.25 (1.01 to 1.55)). Statins (0.77 (0.62 to 0.96)) and TNFi (0.72 (0.54 to 0.97)) were associated with reduction in vertebral fracture risk only. PPIs and other psychotropic medications were not associated with increased fracture risk. CONCLUSION: Use of opioids, SSRIs and glucocorticoids were associated with increased risk of any fracture in patients with RA, whereas statins and TNFi were associated with decreased vertebral fractures.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Ozen G, Pedro S, Wolfe F, et al. Medications associated with fracture risk in patients with rheumatoid arthritis. Ann Rheum Dis. 2019. PMID: 31092411. doi:10.1136/annrheumdis-2019-215328

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。